Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034419 | 0.84 | ADORA3 (0.70) | ADORA2AADORA2BADORA3ADORA1CYP1A2 | |
| SCHEMBL5034108 | 0.84 | ADORA3 (0.70) | ADORA2AADORA2BADORA3ADORA1CYP1A2 | |
| SCHEMBL11516417 | 0.84 | ADORA2A (0.77) | ADORA2AADORA2BADORA3ADORA1CYP1A2 | |
| SCHEMBL11516427 | 0.84 | ADORA2A (0.77) | ADORA2AADORA2BADORA3ADORA1CYP1A2 | |
| SCHEMBL5034551 | 0.83 | ADORA3 (0.69) | ADORA2AADORA2BADORA3ADORA1CYP1A2 | |
| SCHEMBL13437799 | 0.82 | ADORA2A (0.68) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL272915 | 0.82 | ADORA2A (0.68) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL13403870 | 0.82 | ADORA2A (0.68) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL19204725 | 0.82 | ADORA2A (0.60) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL24652562 | 0.81 | ADORA2A (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010065959-A1 | METHOD OF PREPARING ADENOSINE-RESISTANT ANTI-TUMOR T LYMPHOCYTES FOR ADOPTIVE IMMUNOTHERAPY | NORTHEASTERN UNIVERSITY (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-2099360-A2 | MYOCARDIAL PERFUSION IMAGING | CV Therapeutics Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| EP-2056834-A1 | METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS | CV THERAPEUTICS, INC. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008086096-A2 | MYOCARDIAL PERFUSION IMAGING | CV THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008028140-A1 | METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS | CV THERAPEUTICS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-1524984-A1 | MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004011010-A1 | MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1189916-A2 | N-PYRAZOLE A 2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000078779-A2 | N-PYRAZOLE A2A RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2000-12-28 | — | — | WO | disclosed |